GlassScriptPhysician profile
Raul Correa
NPI 1245905736
$10,384.18
in general payments reported to CMS, 2019-2025
25 companies · $1,405 in 2025
The $1,405 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,207 · 2022: $2,628 · 2023: $2,478 · 2024: $2,666 · 2025: $1,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,545 · Education: $3.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,545.09 |
| Education | $3.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,644.12 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $1,328.11 | 2023-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $993.08 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $983.91 | 2021-2025 | Caplyta |
| Corium, LLC | $920.07 | 2021-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $833.01 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $652.28 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $623.20 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Alkermes, INC. | $590.68 | 2021-2025 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $481.94 | 2021-2024 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $274.62 | 2023 | Quviviq |
| Lundbeck LLC | $266.38 | 2021-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $155.23 | 2021-2024 | Trintellix |
| Eisai INC. | $142.36 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $141.97 | 2024-2025 | Cobenfy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $67.22 | 2025 | Jornay Pm |
| Genentech USA, INC. | $61.56 | 2021 | |
| Sunovion Pharmaceuticals INC. | $49.56 | 2022 | |
| Almatica Pharma LLC | $48.78 | 2021-2022 | |
| Indivior INC. | $30.49 | 2022 | |
| Tris Pharma INC | $26.50 | 2025 | Onyda Xr |
| Axsome Therapeutics, INC. | $21.11 | 2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $16.70 | 2024 | Fanapt |
| Jazz Pharmaceuticals INC. | $16.12 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Correa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.